Replies to post #122998 on Biotech Values

[ghmm]

I occasionally look in on CRME that closely but had thought Merck was going to go ahead with the Oral program. Do you know if that is still the case? I'll have to try to catch their last call.

[drbio45]

confirms the value or aryx's drug but the management screwed that up royally

[mcbio]

SNY/CRME - Oppenheimer says Multaq issues benefit CRME

[I have my own reservations with CRME, as noted in the prior post.]

http://finance.yahoo.com/news/Cardiome-benefit-Sanofi-trial-theflyonthewall-636436655.html?x=0&.v=1

Cardiome to benefit from Sanofi trial halt, says Oppenheimer

After Sanofi (SNY) announced that a Phase III trial of its Multaq drug for atrial fibrillation was discontinued, Oppenheimer sees the news as positive for Cardiome's (NasdaqGM:CRME) oral vernakalant. The firm thinks that Cardiome is undervalued and it maintains an Outperform rating on the stock.